United Services Automobile Association Lowers stake in Pfizer (PFE)

Pfizer (PFE) : United Services Automobile Association reduced its stake in Pfizer by 3.19% during the most recent quarter end. The investment management company now holds a total of 7,116,926 shares of Pfizer which is valued at $248,950,071 after selling 234,157 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Pfizer makes up approximately 0.85% of United Services Automobile Association’s portfolio.

Other Hedge Funds, Including , Delphi Private Advisors boosted its stake in PFE in the latest quarter, The investment management firm added 47 additional shares and now holds a total of 4,007 shares of Pfizer which is valued at $140,165. Pfizer makes up approx 0.24% of Delphi Private Advisors’s portfolio.Dorsey Whitney Trust Co boosted its stake in PFE in the latest quarter, The investment management firm added 10,125 additional shares and now holds a total of 149,958 shares of Pfizer which is valued at $5,245,531. Pfizer makes up approx 1.17% of Dorsey Whitney Trust Co’s portfolio.Jackson Grant Investment Advisers boosted its stake in PFE in the latest quarter, The investment management firm added 270 additional shares and now holds a total of 13,525 shares of Pfizer which is valued at $479,326. Pfizer makes up approx 0.41% of Jackson Grant Investment Advisers’s portfolio.1st Global Advisors reduced its stake in PFE by selling 7,986 shares or 7.35% in the most recent quarter. The Hedge Fund company now holds 100,677 shares of PFE which is valued at $3,698,873. Pfizer makes up approx 0.50% of 1st Global Advisors’s portfolio.

Pfizer opened for trading at $35 and hit $35.27 on the upside on Tuesday, eventually ending the session at $35.09, with a gain of 0.72% or 0.25 points. The heightened volatility saw the trading volume jump to 1,69,57,889 shares. Company has a market cap of $212,844 M.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.